What Haemo Pharma does

Haemo Pharma GmbH is an Austrian family-owned medical-products distribution company founded in 2006 and headquartered in Eisenstadt, Burgenland, specializing in regenerative medicine. The company distributes a portfolio of more than 150 products organized across viscosupplementation (CINGAL, MONOVISC, ORTHOVISC, ORTHOVISC-T), cartilage therapies (Spherox, HyaloFast, NanoFx), autologous cell-therapy platforms (IMPACT system for PRP/APC/ACS preparations; Miracell stem-cell isolation), orthopedic implants (Parcus Medical), physiotherapy and rehabilitation devices (Zimmer MedizinSysteme Cryo 6/7, enShock, emField Pro, enPuls Pro, Opton Pro; Winback electrotherapy), tissue products (AlloSource allografts), and pharmaceuticals (CitraFleet, CitraFleet Secure, Nipruss, Nubain, SeraSeal). Its most distinctive asset is exclusive Austrian distribution of Spherox, the only Advanced Therapy Medicinal Product (ATMP) approved by the EMA for the treatment of cartilage defects in Europe.

The business operates a B2B field-sales distribution model in which representatives visit orthopedists, sports-medicine physicians, hospitals, clinics, pharmacies, and physiotherapists across Austria. Haemo Pharma holds ISO 9001:2015 (TÜV SÜD), Austrian tissue bank, and pharmaceutical wholesale certifications, enabling legally compliant handling of regulated biological products under a documented cold chain. The company reports serving more than 1,700 physicians and 145 hospitals, with products used to treat over 900,000 patients cumulatively (lifetime, not annual). Pricing is quote-based with no public disclosure; revenue is generated through multi-year contracting with healthcare providers on a transactional product-sales basis.

The firm is bootstrapped and founder-led, with Prof. Dr. Peter Mateyka and Mag. Markus Mateyka as co-founders and the Mateyka family retaining leadership roles. Geographic scope is single-country (Austria); all distribution channels and partnerships are domestic. Commercial execution combines hands-on physician training (HyaloFast Wet Labs at the Medical University of Innsbruck, Cartilage Joint Labs at Orthopädisches Spital Speising), medical congress participation (e.g., AGA Kongress 2026 in Innsbruck), sports-driven brand visibility (sponsorships of Austrian football, basketball, and individual athletes), and a multi-channel digital marketing stack (Google Ads, Meta, LinkedIn, Brevo newsletters). There is no evidence of external funding, M&A activity, or AI/ML capability development in the available data.

Name

Haemo Pharma

Legal name

Haemo Pharma GmbH

Website

https://haemo-pharma.at

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Haemo Pharma GmbH is an Austrian family-owned medical-products distributor (founded 2006) specializing in regenerative medicine — viscosupplements, the EMA-approved cartilage cell therapy Spherox, orthopedic implants, physiotherapy devices, and pharmaceuticals — serving orthopedists, hospitals, and physiotherapists across Austria through field sales.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Distribution

NAICS

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450), Drugs and Druggists' Sundries Merchant Wholesalers (4242), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Regenerative medicine products
• Viscosupplement distribution
• Orthopedic medical devices
• Cartilage cell therapy
• Sports medicine supplies

Headquarters

HQ city

Eisenstadt

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical products distribution: Distribution of regenerative medicine products, medical devices, and pharmaceuticals to healthcare providers including physicians, hospitals, clinics, pharmacies, and physiotherapists. Products include viscosupplements, cartilage therapies, cell therapies, cold air therapy, sports medicine equipment, and surgical implants.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Haemo Pharma distributes a portfolio of 150+ regenerative medicine and medical products to Austrian healthcare providers, including viscosupplements (CINGAL, MONOVISC, ORTHOVISC) for osteoarthritis, the EMA-approved cartilage cell therapy Spherox, HyaloFast and NanoFx cartilage regeneration products, IMPACT/Miracell/Marrow Cellution cell and stem cell therapy systems, Zimmer MedizinSysteme regeneration and cold air therapy devices, Parcus Medical orthopedic implants, and pharmaceuticals such as CitraFleet, Nipruss, Nubain, and SeraSeal. The company supports physicians, hospitals, clinics, pharmacies, and physiotherapists with temperature-controlled logistics, certified tissue bank operations, and field-based product training.

Product overview

Haemo Pharma is an Austrian family-owned company founded in 2006 specializing in regenerative medicine and medical products for physicians, clinics, and therapists. The product portfolio is organized into several therapeutic categories: Viscosupplements (CINGAL®, MONOVISC®, ORTHOVISC®, ORTHOVISC® mini, ORTHOVISC®-T) for osteoarthritis and joint therapy; Cartilage therapies including Spherox (the only EMA-approved ATMP for cartilage defects), HyaloFast®, NanoFx®, and Chondrectom™ surgical tools; Cell therapy platforms including IMPACT® system with products for ACS, APC, and PRP treatments, plus Miracell® stem cell isolation and Marrow Cellution™ extraction systems; Tissue products (Allografts); Regeneration therapy devices from Zimmer MedizinSysteme including enShock, Winback, emField Pro, enPuls Pro, and Opton Pro; Cold air therapy devices (Cryo 6, Cryo 7); Orthopedic implants via Parcus Medical partnership; and pharmaceuticals including CitraFleet® bowel preparations, SeraSeal™ hemostatic agent, and pain management products (Nipruss®, Nubain®). The company also provides temperature-controlled logistics, application support, and training services.

Differentiator

Problem solved

Functional benefit

Products and services

• CINGAL® Single-injection viscosupplement combining hyaluronic acid and corticosteroid for rapid and long-lasting pain relief in activated osteoarthritis. Targeted at orthopedic physicians treating joint pain.
• MONOVISC® Single-injection hyaluronic acid viscosupplement for osteoarthritis treatment. For orthopedic physicians treating joint pain.
• ORTHOVISC® Hyaluronic acid viscosupplement for arthrosis therapy and joint treatment. Targeted at orthopedic physicians.
• ORTHOVISC® mini Hyaluronic acid viscosupplement designed for arthritis therapy in small joints. Targeted at orthopedic physicians treating smaller joints.
• ORTHOVISC®-T Hyaluronic acid injection for treatment of tendopathies (tendon disorders). For orthopedic physicians and sports medicine doctors.
• Spherox EMA-approved cartilage cell therapy and the only EMA-approved Advanced Therapy Medicinal Product (ATMP) for cartilage defect treatment. Personalized autologous cartilage cell therapy where patient cells are isolated, cultured, and transplanted as spheroids to integrate with healthy cartilage. For orthopedic surgeons treating cartilage defects.
• HyaloFast® 3D hyaluronic acid fiber matrix layer enabling single-step matrix-assisted cartilage replacement for cartilage regeneration. For orthopedic surgeons treating cartilage defects.
• NanoFx® Nanofracturing surgical technique for cartilage regeneration. For orthopedic surgeons performing cartilage repair procedures.
• Chondrectom™ Surgical instruments for precise cartilage processing during cartilage repair procedures. For orthopedic surgeons.
• Allografts High-quality allograft tissue products sourced from AlloSource for transplantation and surgical procedures. For hospitals and surgeons performing tissue transplantation.
• IMPACT® Cell Therapy Platform Platform system enabling preparation of various autologous blood-derived cell therapies. For physicians and clinics performing autologous cell therapy procedures.
• IMPACT® ACS Autologous Conditioned Serum prepared using the IMPACT platform for therapeutic applications in regenerative medicine. For orthopedic physicians treating joint inflammation and pain.
• IMPACT® APC Autologous Platelet Concentrate prepared using the IMPACT platform for therapeutic applications. For orthopedic physicians treating musculoskeletal conditions.
• IMPACT® PRP Platelet-Rich Plasma prepared using the IMPACT platform for regenerative treatments. For orthopedic and sports medicine physicians.
• Miracell® Innovative stem cell isolation system for extracting and processing patient's own cells for regenerative orthopedics. For orthopedic surgeons performing cell-based regenerative therapies.
• Marrow Cellution™ Stem cell extraction device for efficient harvesting of stem cells from bone marrow. For orthopedic surgeons and regenerative medicine practitioners.
• enShock Focused shockwave therapy device for regenerative treatments. For physiotherapists and sports medicine practitioners.
• Winback Regenerative multifrequency electrotherapy device for physiotherapy and rehabilitation applications. For physiotherapy practices.
• emField Pro Focused magnetic field therapy device for regenerative and rehabilitation treatments. For physiotherapy practices and clinics.
• enPuls Pro Mobile shockwave therapy device for regenerative treatments on the go. For physiotherapy and sports medicine practitioners.
• Opton Pro Laser device for physical biostimulation in physiotherapy and rehabilitation settings. For physiotherapy practices and clinics.
• Cryo 6 User-friendly and resource-saving cold air therapy device for targeted cryotherapy treatments. For physiotherapy practices, sports medicine, and clinics.
• Cryo 7 Effective cold air therapy device for targeted cryotherapy treatments. For physiotherapy practices, sports medicine, and clinics.
• Parcus Medical Orthopedic Implants Orthopedic implants and instruments for sports medicine covering shoulders, knees, hips, and distal extremities. Includes suture anchors, interference screws, graft fixation systems, and tenodesis systems made from biocompatible materials including carbon-fiber-reinforced PEEK-OPTIMA. For orthopedic surgeons.
• Nipruss® Pharmaceutical product for pain therapies. For hospitals and clinicians managing acute pain.
• Nubain® Pharmaceutical product for pain therapies. For hospitals and clinicians managing moderate-to-severe pain.
• SeraSeal™ Hemostatic agent for effective blood clotting during surgical procedures. For hospitals and surgical teams.
• CitraFleet® Bowel cleansing preparation for diagnostic examinations, containing sodium picosulfate, magnesium oxide, and citric acid in powder form for oral solution preparation. For pharmacies and gastroenterology departments.
• CitraFleet® Secure Fast-acting, well-tolerated bowel cleansing preparation for diagnostic examinations using a two-bag protocol for thorough and gentle cleansing before procedures. For pharmacies and gastroenterology departments.

Quantifiable outcome

• 1,700+ satisfied physicians use Haemo Pharma products
• +3 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Zimmer MedizinSystemecoreTechnology or IntegrationPartner for medical devices including Cryo 6 and Cryo 7 cold air therapy devices, enShock and enPuls Pro shockwave therapy devices, emField Pro magnetic field therapy, and Opton Pro laser therapy systems.
• AnikacoreTechnology or IntegrationPartner for viscosupplementation products including MONOVISC, ORTHOVISC, and ORTHOVISC mini hyaluronic acid injections for osteoarthritis treatment.
• MiraCellcoreTechnology or IntegrationPartner for Miracell stem cell isolation system for innovative cell-based therapies in regenerative medicine.
• AlloSourcecoreTechnology or IntegrationPartner for high-quality allograft tissue products for transplantation and surgical procedures.
• WinbackcoreTechnology or IntegrationPartner for Winback regenerative multifrequency electrotherapy devices for physiotherapy applications.
• CondonminorChannel Partner/ Reseller/ DistributorDistribution partner for medical products in specific therapeutic areas.
• Parcus MedicalcoreTechnology or IntegrationPartner for orthopedic implants and instruments for sports medicine including suture anchors, interference screws, and graft fixation systems. Products available in over 60 countries.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Arthrex: Global leader in orthopedic surgical products including orthobiologics (PRP, BMAC), suture anchors, and cartilage repair. Comparable as a broad incumbent in the same sports-medicine/orthopedic device categories Haemo Pharma distributes (e.g., Parcus implants compete with Arthrex).
• Anika Therapeutics: US manufacturer of MONOVISC, ORTHOVISC, and CINGAL viscosupplements — the upstream supplier for Haemo Pharma's largest product family. Comparable as the originator of the viscosupplement line being distributed, competing with Haemo Pharma's marketing reach via direct strategies.
• Aesculap Biologics (B. Braun): Division of B. Braun providing regenerative medicine products for cartilage and bone repair. Comparable to Haemo Pharma as a broad incumbent offering overlapping regenerative therapies in orthopedics through established hospital channels.
• Smith+Nephew: Global medtech company with a strong orthobiologics and sports medicine portfolio (including cartilage repair). Comparable as a broad incumbent supplying hospitals with overlapping regenerative and orthopedic product lines.

Direct peers

• CO.DON AG: German regenerative medicine company focused on autologous chondrocyte implantation (Chondrosphere/Spherox-adjacent technology). Comparable to Haemo Pharma as a European specialist in cartilage cell therapy products.
• Eumedics Pharma: Austrian specialty pharma and medical products distributor focused on niche hospital and physician channels. Comparable to Haemo Pharma as a domestic Austrian specialty distribution counterpart serving the same hospital and clinic customer base.
• Vericel Corporation: US developer of autologous cell therapies including MACI for cartilage defects — the principal competitive cell therapy to Spherox. Comparable as a specialist regenerative medicine franchise built around autologous chondrocyte implantation and sports-medicine distribution.
• curasan AG: German specialty distributor and developer of orthobiologics and regenerative medicine products for bone and cartilage. Comparable to Haemo Pharma as a DACH-focused regenerative medicine specialist with a similar portfolio of regenerative therapies and surgical biomaterials.
• Geistlich Pharma: Swiss regenerative medicine company in cartilage, bone, and dental regeneration (e.g., Bio-Gide, Chondro-Gide). Comparable to Haemo Pharma as a DACH-based regenerative medicine specialist distributing to hospitals and specialist physicians.

Others

• Riemser Pharma (Esteve): European specialty pharmaceutical company with hospital-focused distribution capabilities. Comparable to Haemo Pharma as a specialty pharma distributor; included as a relevant distribution-adjacent peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/haemopharma
• LinkedInlinkedin.com/company/haemo-pharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haemo Pharma